Effect of chronic and short-term erythropoietin treatment on random flap survival in rats: An experimental study

Laryngoscope

Volumn 113, Issue 1, 2003, Pages 85-89

  Saray, Aydin ^a,c   Ozakpinar, Rifat ^b   Koc, Can ^a   Serel, Savas ^b   Sen, Zeynep ^b   Can, Zeki ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c Konutkent 2 ^*  (Turkey)

Author keywords

Erythropoietin; Random skin flap; Survival

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE; DRUG EFFICACY; GRAFT FAILURE; GRAFT SURVIVAL; LONG TERM CARE; MEASUREMENT; MYOCUTANEOUS FLAP; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RAT; RAT STRAIN; TISSUE NECROSIS;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; INJECTIONS, SUBCUTANEOUS; MALE; POSTOPERATIVE CARE; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, INBRED STRAINS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURGICAL FLAPS;

EID: 0037221087     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200301000-00016     Document Type: Article

References (30)

1. von Doersten P, Cruz RM, Selby JV, Hilsinger RL. Transfusion, recurrence, and infection in head and neck cancer surgery. Otolaryngol Head Neck Surg 1992;106:60-67.
2. Koestner JA, Nelson LD, Morris JA, Safcsak K. Use of recombinant human erythropoietin (r-HuEPO) in a Jehovah's Witness refusing transfusion of blood products: Case report. J Trauma 1990;30:1406-1408.
3. Genden EM, Haughey BH. Head and neck surgery in the Jehovah's Witness patient. Otolaryngol Head Neck Surg 1996;114:669-672.
4. Goodnough LT. Clinical application of recombinant erythropoietin in the perioperative period. Hematol Oncol Clin North Am 1994;8:1011-1020.
5. Sturgis EM, Gianoli GJ, Miller RH, Fisher JW. Avoiding transfusion in head and neck surgery: Feasibility study of erythropoietin. Laryngoscope 2000;110:51-57.
6. Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989;321:1163-1168.
7. Huang C, Davis G, Johns EJ. Role of haematocrit in mediating the actions of chronic erythropoietin treatment on blood pressure and renal haemodynamics in the rat. Clin Sci 1993;85:717-724.
8. Vaziri ND, Zhou XJ, Naqvi F, et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 1996;271(Endocrinol Metab 34):E113-E122.
9. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76:1718-1722.
10. Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989;73:90-99.
11. van Geet C, Hauglustaine D, Verresen L, Vanrusselt M, Vermylen J. Hemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemostasis 1989;61:117-121,
12. Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ. Nitric oxide mediates renal vasodilation during erythropoietin-induced polycytemia. Kidney Int 1993;44:403-435.
13. Wada Y, Matsuoka H, Tamai O, Kohno K, Okuda S, Imaizumi T. Erythropoietin impairs endotheliumdependant mechanisms in humans. Am J Hypertension 1999;12:980-987,
14. Joannides R, Bakkali EH, LeRoy F, et al. Altered flow-dependent vasodilation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 1997;12:2623-2628.
15. Migliori M, Taccola D, Panichi V, et al. Nitric oxide-dependent renal vasodilation is not altered in the rat with rHuEPO-induced hypertension. Kidney Blood Press Res 1999;22:140-145.
16. Nagai T, Akizawa T, Nakashima Y, et al. Effects of rHuEPO on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transplant 1995;10:1814-1819.
17. Takahashi S, Yanai M, Okada K. Recombinant human erythropoietin has no direct or strong vasoconstrictor effects in vivo and in vitro. Nephrol Dial Transplant 1995;10:815-820.
18. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictive tone via endothelin-1 and constrictor protanoids. Kidney Int 1996;50:1255-1261.
19. Raine R. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1988;1:97-100.
20. Nonnast-Daniel B, Creutzig A, Kühn K, et al. Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation. Contr Nephrol 1988;66:185-194.
21. Grutzmacher P, Bergmann M, Weinreich T, Nattermann U, Reimers E, Pollok M. Beneficial and adverse effects of correction of anemia by recombinant human erythropoietin in patients on maintenance dialysis. Contr Nephrol 1988;66:104-113.
22. Johnson WJ, McCarthy JT, Yanagihara T, et al. Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int 1990;38:919-924.
23. Awwad AM, White RJ, Lowe GDO, Forbes CD. The effect of blood flow viscosity on blood flow in the experimental saphenous flap model. Br J Plast Surg 1983;36:383-386.
24. Ramasastry SS, Waterman P, Angel MF, Futrell JW. Effect of fluosol-DA (20%) on skin flap survival in rats. Ann Plast Surg 1985;15:436-442.
25. Earle AS, Fratianne B, Nunez FD. The relationship of hematocrit levels to skin flap survival in the dog. Plast Reconstr Surg 1974;54:341-344.
26. Bany-Mohammed FM, Slivka S, Hallman M. Recombinant human erythropoietin: Possible role as an antioxidant in premature rabbits. Pediatr Res 1996;40:381-387.
27. Calapai G, Marciano MC, Corica F, et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000;401:349-356.
28. Gillespie JS, Sheng H. Influence of haemoglobin and erythrocytes on the effects of EDRF, a smooth muscle inhibitory factor, and nitric oxide on vascular and non-vascular smooth muscle. Br J Pharmacol 1988;95:1151-1156.
29. Tsukahara H, Hiraoka M, Hori C, et al. Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. Scand J Clin Lab Invest 1997;57:487-493.
30. Reinhart WH. Shear-dependence of endothelial functions. Experientia 1994;50:87-93.